Evidence map›Paper›PMID 35926508›Full record

ArticleImmunity2022

The transcription factor FoxP3 can fold into two dimerization states with divergent implications for regulatory T cell function and immune homeostasis.

Fangwei Leng, Wenxiang Zhang, Ricardo N Ramirez, Juliette Leon, Yi Zhong, Lifei Hou, Koichi Yuki, Joris van der Veeken, Alexander Y Rudensky, Christophe Benoist and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Inborn errors of regulatory T-cell differentiation and function.The Journal of allergy and clinical immunology · 2025
    Review
  9. Article
  10. Review
  11. A Fkh1/2 binding site array in thebioRxiv : the preprint server for biology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Fangwei LengHoward Hughes Medical Institute and Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Wenxiang ZhangHoward Hughes Medical Institute and Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Ricardo N RamirezDepartment of Immunology, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Juliette LeonDepartment of Immunology, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Yi ZhongHoward Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA; Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lifei HouDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Koichi YukiDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Joris van der VeekenResearch Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.
Alexander Y RudenskyHoward Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christophe BenoistDepartment of Immunology, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Sun HurHoward Hughes Medical Institute and Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: sun.hur@crystal.harvard.edu.
Boston Children's Hospital · USBrigham and Women's Hospital · USHoward Hughes Medical Institute · USHarvard University · USMemorial Sloan Kettering Cancer Center · USResearch Institute of Molecular Pathology · AT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SELF PEPTIDES BOUND TO MHC CLASS II IN T CELL SELECTIONR01AI034206 · NIAID · UNIVERSITY OF WASHINGTON · PI Alexander Y Rudensky · 1998 to 2026
$6.4M
Resolving functional aggregates: A new perspective on innate immune controlDP1AI152074 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUR, SUN · 2019 to 2023
$6.2M
Structural and functional analyses of the RIG-I filament in innate immunityR01AI111784 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUR, SUN · 2014 to 2023
$4.9M
Treg cell diversity and homeostatic controlR01AI150686 · NIAID · HARVARD MEDICAL SCHOOL · PI BENOIST, CHRISTOPHE O. · 2020 to 2024
$2.6M
Specification of Treg cells: FOXP3 functional facetsR01AI116834 · NIAID · HARVARD MEDICAL SCHOOL · PI BENOIST, CHRISTOPHE O. · 2015 to 2019
$2.3M
Molecular mechanisms for antiviral signaling and regulation by MDA5 and TRIM65R01AI154653 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUR, SUN · 2020 to 2024
$2.2M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NIAID NIH HHS DP1 AI152074NIAID NIH HHS R01 AI034206NIAID NIH HHS R01 AI111784NIAID NIH HHS R01 AI116834NIAID NIH HHS R01 AI150686NIAID NIH HHS R01 AI154653
6 · The paper itself

Abstract

FoxP3 is an essential transcription factor (TF) for immunologic homeostasis, but how it utilizes the common forkhead DNA-binding domain (DBD) to perform its unique function remains poorly understood. We here demonstrated that unlike other known forkhead TFs, FoxP3 formed a head-to-head dimer using a unique linker (Runx1-binding region [RBR]) preceding the forkhead domain. Head-to-head dimerization conferred distinct DNA-binding specificity and created a docking site for the cofactor Runx1. RBR was also important for proper folding of the forkhead domain, as truncation of RBR induced domain-swap dimerization of forkhead, which was previously considered the physiological form of FoxP3. Rather, swap-dimerization impaired FoxP3 function, as demonstrated with the disease-causing mutation R337Q, whereas a swap-suppressive mutation largely rescued R337Q-mediated functional impairment. Altogether, our findings suggest that FoxP3 can fold into two distinct dimerization states: head-to-head dimerization representing functional specialization of an ancient DBD and swap dimerization associated with impaired functions.

Indexed as

Core Binding Factor Alpha 2 SubunitT-Lymphocytes, RegulatoryDimerizationDNAForkhead Transcription FactorsHomeostasisCore Binding Factor Alpha 2 SubunitDNAForkhead Transcription FactorsforkheadFoxp3homodimerIPEXRunx1transcription factorTreg

Identifiers

PMID35926508
PMCPMC9907729
OpenAlexW4289688738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.